Abstract
Highly publicised vaccine scares and recent debates about the risks suggest that public trust in immunisation programmes is fragile. For instance, the recent outbreak of Measles in Wales was the direct result of almost fifteen years of distrust for the MMR vaccine in the UK. This article shows how the latest science on risk communication will help critical actors, especially policy-makers, to build trust when they communicate risks to citizens and patients. The article offers policy advice on risk communication based on the results of three vaccines case studies. Five procedural principles which were developed for the UK government – the so-called “five As” of public risk communication are used to structure the discussion. Conclusions and recommendations suggest ways to move forward and build a two-way proactive risk communication practice.
Keywords: Hepatitis B, HPV, MMR, policy, regulation, risk communication, trust.
Current Drug Safety
Title:Risk Communication of Vaccines: Challenges in the Post-Trust Environment
Volume: 10 Issue: 1
Author(s): Frederic Bouder
Affiliation:
Keywords: Hepatitis B, HPV, MMR, policy, regulation, risk communication, trust.
Abstract: Highly publicised vaccine scares and recent debates about the risks suggest that public trust in immunisation programmes is fragile. For instance, the recent outbreak of Measles in Wales was the direct result of almost fifteen years of distrust for the MMR vaccine in the UK. This article shows how the latest science on risk communication will help critical actors, especially policy-makers, to build trust when they communicate risks to citizens and patients. The article offers policy advice on risk communication based on the results of three vaccines case studies. Five procedural principles which were developed for the UK government – the so-called “five As” of public risk communication are used to structure the discussion. Conclusions and recommendations suggest ways to move forward and build a two-way proactive risk communication practice.
Export Options
About this article
Cite this article as:
Bouder Frederic, Risk Communication of Vaccines: Challenges in the Post-Trust Environment, Current Drug Safety 2015; 10 (1) . https://dx.doi.org/10.2174/157488631001150407103916
DOI https://dx.doi.org/10.2174/157488631001150407103916 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
History and Milestones of Mouse Models of Autoimmune Diseases
Current Pharmaceutical Design Dystroglycan, A Multifunctional Adaptor Protein for Signal Transduction and A Potential Therapeutic Target
Current Signal Transduction Therapy Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis
Current Pharmaceutical Design The Dendritic Cell-T Cell Synapse as a Determinant of Autoimmune Pathogenesis
Current Pharmaceutical Design Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Humanized Cobra Venom Factor: Experimental Therapeutics for Targeted Complement Activation and Complement Depletion
Current Pharmaceutical Design Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry Therapeutic Nanotechnology for Bone Infection Treatment – State of the Art
Current Drug Delivery Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Is Helicobacter pylori the Infectious Trigger for Headache?: A Review
Infectious Disorders - Drug Targets Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Recent Advances on the Possible Neuroprotective Activities of Epstein- Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System
Current Neuropharmacology Influence of Usnic Acid and its Derivatives on the Activity of Mammalian Poly(ADP-ribose)polymerase 1 and DNA Polymerase β
Medicinal Chemistry A Review on Clinical Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody
Current Drug Metabolism Gender Hormones: Role in the Pathogenesis of Central Nervous System Disease and Demyelination
Current Neurovascular Research The Biochemical Mechanisms of T-Cell Anergy
Current Immunology Reviews (Discontinued) Mouse Models of Multiple Sclerosis: Lost in Translation?
Current Pharmaceutical Design Aquaporins and Neurodegenerative Diseases
Current Neuropharmacology